Money

Found 79,792 articles

• Propanc Biopharma Announces Reverse Stock Split - May 23, 2023

  5/23/2023

  Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s board of directors has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.

• Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - May 23, 2023

  5/23/2023

  Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.

• Agile Therapeutics Announces Pricing of $7.5 Million Public Offering

  5/23/2023

  Agile Therapeutics, Inc., a women's healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.

• Immunovia Publishes Interim Report for January-March 2023

  5/23/2023

  Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60).

• Nordson Corporation Reports Second Quarter Fiscal 2023 Results and Updates Annual Guidance

  5/22/2023

  Nordson Corporation reported results for the fiscal second quarter ended April 30, 2023. Sales were $650 million, a 2% increase compared to the prior year’s second quarter sales of $635 million.

• Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

  5/22/2023

  Cabaletta Bio, Inc. announced the closing of an underwritten public offering of 8,337,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares, at the public offering price of $12.00 per share.

• Guardant Health Announces Proposed Public Offering of Common Stock - May 22, 2023

  5/22/2023

  Guardant Health, Inc., a leading precision oncology company, announced that it has commenced an underwritten public offering of $250.0 million of its common stock.

• Kelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products

  5/22/2023

  Kelyniam Global, a leading maker of custom cranial implants, announced results for its quarter ended March 31, 2023.

• 7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

  5/22/2023

  7 Hills Pharma LLC announced that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention & Research Institute of Texas to advance 7HP349, its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies.

• Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

  5/22/2023

  Navidea Biopharmaceuticals, Inc. announced the sale of Preferred Shares totaling $1.1 million to new existing investors, further supporting the Company’s Fix, Fund, Propel approach and helping to advance Navidea’s innovative technology to market.

• Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 22, 2023

  5/22/2023

  Avidity Biosciences, Inc. announced that on May 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 36,900 shares of its common stock and 18,450 restricted stock units to eight new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.

• G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

  5/22/2023

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer.

• GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

  5/22/2023

  GeneDx announced that it had received a letter from The Nasdaq Stock Market LLC stating that, because the Company’s Class A common stock had a closing bid price at or above $1.00 per share for a minimum of ten consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450, and that the matter is now closed.

• Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer

  5/22/2023

  Lifecore Biomedical, Inc. announced that it has entered into a broad set of agreements with its long-term customer, Alcon, which provides for the repayment of the Company’s existing credit agreement with its current lenders and substantially increases the amount of hyaluronic acid that Lifecore is expected to supply for use in Alcon’s commercial products.

• Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

  5/22/2023

  Icosavax, Inc. announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share.

• Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

  5/22/2023

  Akebia Therapeutics®, Inc. announced that it has received a formal notice from The Nasdaq Stock Market stating that Akebia has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550, and that Akebia is in compliance with all applicable listing standards.

• Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT

  5/22/2023

  Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced that it will host a conference call to discuss fiscal 2023 third quarter financial results.

• PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases

  5/22/2023

  PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need.

• Microbot Medical Announces $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

  5/22/2023

  Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 655,569 shares of the Company’s common stock at a purchase price of $2.20 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

• LEADOPTIK Raises $5 Million in Series Seed Funding to Advance Early Lung Cancer Detection with Cutting-Edge Imaging Technology

  5/22/2023

  LEADOPTIK Inc., a Silicon Valley-based medical imaging company today announced that it has raised $5 million in an oversubscribed series seed funding, led by MetaVC Partners with participation from SOSV, Sony Innovation Fund, TSVC, ENEA, Arash Ferdowsi (co-founder of Dropbox), Ray Muzyka (co-founder of BioWare), and others.